Canaccord Genuity downgraded shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from a buy rating to a hold rating in a research report report published on Friday, Marketbeat reports. They currently have $135.00 price objective on the medical equipment provider’s stock, down from their prior price objective of $141.00.

A number of other brokerages have also commented on ZBH. Morgan Stanley lifted their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an overweight rating in a report on Monday, July 17th. Stifel Nicolaus reiterated a hold rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Piper Jaffray Companies reiterated a buy rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Royal Bank Of Canada reiterated an outperform rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Wells Fargo & Company reiterated a market weight rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $137.76.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 121.32 on Friday. The company’s 50 day moving average price is $127.79 and its 200-day moving average price is $121.35. The firm has a market capitalization of $24.48 billion, a price-to-earnings ratio of 34.55 and a beta of 1.21. Zimmer Biomet Holdings has a 12-month low of $95.63 and a 12-month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.02 earnings per share. On average, equities analysts anticipate that Zimmer Biomet Holdings will post $8.36 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Downgraded to “Hold” at Canaccord Genuity” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-nysezbh-downgraded-to-hold-at-canaccord-genuity/1465053.html.

The business also recently declared a quarterly dividend, which was paid on Friday, July 28th. Stockholders of record on Friday, June 23rd were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend was Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

In other news, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Chad F. Phipps sold 6,200 shares of Zimmer Biomet Holdings stock in a transaction on Friday, May 5th. The shares were sold at an average price of $116.76, for a total value of $723,912.00. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC increased its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the last quarter. Sandy Spring Bank increased its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares during the last quarter. Finally, Penserra Capital Management LLC increased its stake in shares of Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 112 shares during the last quarter. Institutional investors and hedge funds own 84.13% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.